Introduction {#s1}
============

Advances in radiation technology like intensity modulated radiation therapy (IMRT) and image guided RT (IGRT) have facilitated improved sparing of healthy surrounding tissues and organs. Nonetheless, radiation pneumonitis and esophagitis remain the most common dose-limiting toxicities in thoracic RT ([@B1]--[@B6]). Concurrent chemoradiation significantly increases the risk of developing pneumonitis or esophagitis compared to radiation alone ([@B7], [@B8]).

The reported incidence of pneumonitis after definitive thoracic RT ranges from 10 to 20%, although figures can vary greatly ([@B3], [@B9]--[@B13]). This is partly because pneumonitis remains a clinical diagnosis; there are no biomarkers or radiological findings that unequivocally confirm its presence. Medical intervention is required for patients with grade two or higher radiation pneumonitis, and severe cases can lead to fatal outcomes \[Common Terminology Criteria for Adverse Events (CTCAE) v4.03, [Supplementary Material 1](#SM1){ref-type="supplementary-material"}\]. Significant esophageal toxicity (grade 3--5) occurs in around 4% of patients with sequential chemotherapy and RT and in 18--22% of patients with concurrent chemoradiation ([@B5], [@B14]). Most patients experience mild symptoms like dysphagia and odynophagia while still undergoing radiation. Commonly opioids are used to control symptoms, but in severe cases, tube feeding or surgical intervention can be necessary ([Supplementary Material 1](#SM1){ref-type="supplementary-material"}).

To reduce dose-limiting toxicity in thoracic radiation, efforts have been made to adhere to normal tissue constraints derived from dose volume correlations with clinical toxicities ([@B15]). However, dose volume histograms do not fully predict clinical toxicities, as great interindividual variation remains. Intrinsic predictors of normal tissue radiation response may explain the variation and should be further analyzed.

Radioprotective agents, both natural and synthetic, can present an alternative method to prevent radiation-induced toxicity. Although this has been an active field of research for decades, only two compounds, amifostine and palifermine, are FDA-approved for the use in radiation therapy and neither is commonly used in routine thoracic RT ([@B16]--[@B19]). Another compound under investigation is alpha-2-Macroglobulin (A2M), a postulated intrinsic radioprotector. Human A2M is a glycoprotein and the largest non-immunoglobulin serum protein. In animal studies, A2M has exhibited radioprotective effects in healthy irradiated tissue. In studies with rats that underwent full body irradiation to 6.7 Gy, rats with endo- or exogenously increased levels of A2M had a higher rate of survival, regained their baseline body weight and lymphocyte count faster, and displayed normal proliferative ability of the liver tissue compared to the control groups with normal A2M levels ([@B20]--[@B22]). Suggested key mechanisms supporting the potential of A2M as a radioprotector include promoting expression of antioxidant enzymes, inhibiting fibroblast activation thus preventing fibrosis, deactivating pro-inflammatory cytokines, and enhancing DNA and cell repair mechanisms ([@B23]). Our previous study in a small cohort showed a correlation of A2M with radiation pneumonitis ([@B9]). Smoking can potentially increase A2M levels. However, literature specifically on A2M in smokers remains rare. Some studies confirmed higher A2M levels in smokers compared to non-smokers ([@B24]--[@B26]).

We investigated whether pre-treatment serum A2M levels are an independent predictive variable for the development of post-radiation toxicity in the lung and esophagus in a large cohort of patients receiving thoracic RT.

Materials and Methods {#s2}
=====================

Patients
--------

Clinical, laboratory, treatment and toxicity data were systematically collected in a series of thoracic RT patients between 2012 and 2016 during standard treatment and follow-up procedures. Patients were treated with either conventionally fractionated RT using 3D conformal RT (3DCRT) or intensity-modulated RT (IMRT), or with stereotactic body RT (SBRT). Patients with any prior thoracic RT were excluded. Serum samples for A2M analysis were collected at baseline prior to fraction \#1 of RT. We obtained a retrospective institutional review board waiver to analyze the data. Toxicity data consist of radiation pneumonitis and esophagitis rates graded per CTCAE v4.03. Data were obtained at baseline and at routine follow-up visits every 3 months for the first 2 years.

Alpha-2-Macroglobulin
---------------------

Serum samples were taken ≤ 30 days prior to RT start, typically at the time of simulation. The mean and standard deviation between A2M measurement date and RT start date were 14 and 6 days, respectively. CLIA (Clinical Laboratory Improvement Amendments) approved A2M testing was performed at Quest Diagnostics Nichols Institute (San Juan Capistrano, CA). A2M levels were given in mg/dL; the normal range was defined as 100--280 mg/dL.

Treatment Plans
---------------

For patients treated before 2014, treatment plans were retrieved from our in-house planning system ([@B27]). From 2014 onwards, treatments were planned in the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA). To analyze dosimetric data, treatment plans were imported to the research platform CERR (Computational Environment for Radiological Research) for computing dosimetric variables ([@B28]). Dosimetric variables were extracted from target structures: complete esophagus for esophagitis and "lung minus gross tumor volume (GTV)" and heart for pneumonitis. Before that, plan doses were converted to equivalent dose in 2 Gy fractions (EQD2) with α/β ratio of 10 for esophagus and 3 for lung minus GTV and heart ([@B29]). As radiation esophagitis tends to develop acutely during radiotherapy, one more set of dosimetric variables for esophagus was extracted in addition to the planned doses. For these fractional variables (denoted by the prefix "f," e.g., fmax dose) we divided the dose volume histogram (DVH) bins by the number of treatment days between the start of RT and the end of RT including weekends.

Statistical Methods
-------------------

Univariate and multivariate analyses were performed to investigate associations between toxicity (esophagitis and pneumonitis) and A2M levels, clinical, and dosimetric variables. Patients were categorized into two groups for each endpoint: non-toxicity (grade \<2) and clinically significant toxicity (grade ≥2).

A Wilcoxon rank-sum test was used to find a difference in A2M expression between the two groups. Spearman\'s correlation (Rs) test was used to assess associations between endpoints, Dx values (minimum dose to the volume with the x% hottest dose in the organ of interest), computed from *x* = 5% to *x* = 100% in intervals of 5%, mean dose, max dose, clinical variables, and A2M. For this test CTCAE grades 0--5 were used instead of dichotomized values (grade \<2 and grade ≥2).

Multivariate analysis using the least absolute shrinkage and selection operator (LASSO) logistic regression was performed using features with *p* \< 0.1 that resulted from the univariate Spearman\'s correlation test. To avoid variable instability due to high collinearity, Pearson\'s correlation test was conducted among all dosimetric variables before the multivariate analysis. A cutoff of Pearson\'s correlation coefficient \>0.75 was used to determine a relatively small group of variables for further LASSO modeling, by selecting a single variable that has the best correlation with the endpoint among a set of correlated variables after hierarchical clustering.

To rigorously verify model validity, the data were split into two groups (training data with 2/3 and validation data with 1/3 of samples). The training and validation data were balanced with cancer subtypes and outcomes. This split was performed separately for pneumonitis and esophagitis. The model building process was carried out using only the training data. Furthermore, to examine the stability of LASSO variable selection, the model building process was conducted using a bootstrapped dataset generated from the training data. Finally, the validation data were tested on the resulting model, quantified by the area under the receiver operating characteristic curve (AUC) as a function of true positive rate (sensitivity) and false positive rate (1-specificity). The final reported results represent the average performance on the validation data for predictive models built using 1,000 bootstrapped datasets.

For statistical analyses, R language (version 3.2.4), MATLAB (version 8.6.0; MathWorks. Natick, MA) and SPSS (version 24; IBM. Armonk, NY) were used.

Results {#s3}
=======

Patient Characteristics
-----------------------

In total, 258 patients were eligible for analysis. Most patients were former (*n* = 179, 69.4%) or current smokers (*n* = 32, 12.4%). One hundred and thirty-four patients (51.9%) underwent chemotherapy in addition to RT and the median total RT dose was 54 Gy (range: 27--74 Gy) for conventional fractionation and 50 Gy (range: 30--70 Gy) for SBRT. The median A2M level was 191 mg/dL (range: 94--511 mg/dL). The median follow-up was 8.9 months (range: 0.2--40.2; calculated from the start of RT). More details are available in [Table 1](#T1){ref-type="table"}.

###### 

Patient characteristics.

  **Factor**                                              ***N***                                              **%**
  ------------------------------------------------------- ---------------------------------------------------- -------
  Age \[median, range\]                                   69 (25--93) years                                    
  Sex                                                                                                          
     Male                                                 122                                                  47.3
     Female                                               136                                                  52.7
  KPS \[median, range\]                                   90 (50--100) %                                       
  Subgroups                                                                                                    
     NSCLC                                                202                                                  78.3
     SCLC                                                 17                                                   6.6
     Thymoma                                              8                                                    3.1
     Mesothelioma                                         25                                                   9.7
     Lung metastases (other primary)                      6                                                    2.3
  Smoking history                                                                                              
     Never                                                47                                                   18.2
     Former                                               179                                                  69.4
     Current                                              32                                                   12.4
  Pack-years (former/current smokers) \[median, range\]   37 (1--204) years                                    
  Alpha-2-macroglobulin \[median, range\]                 191 (94--511) mg/dL                                  
  Chemotherapy timing                                                                                          
     Concurrent                                           60                                                   23.2
     Sequential                                           74                                                   28.7
     No chemotherapy                                      124                                                  48.1
  RT total dose \[median, range\]                                                                              
     Conventional RT                                      54 (27--74) Gy                                       
     SBRT                                                 50 (30--70) Gy                                       
  Follow-up time (from start of RT) \[median, range\]     8.9 (0.2--40.2) months                               
  Time to toxicity \[median\]                             1.0 months (esophagitis), 3.6 months (pneumonitis)   

Toxicities
----------

Fifty-third patients (20.5%) experienced grade two and eight (3.1%) grade three radiation esophagitis. No grade four or five esophagitis was observed. Median time to development of esophagitis was 0.85 months after the start of RT (range: 0.2--6.47 months). Grade two radiation pneumonitis developed in 26 patients (10.1%), grade three in nine (3.5%) and grade four in one patient (0.4%). No grade five pneumonitis was observed. Median time to development of pneumonitis was 4.7 months after the start of RT (range: 1.3--8.1 months).

Of the patients who developed grade ≥2 esophagitis, 8 (13.1%) were never, 43 (70.5%) former and 10 (16.4%) current smokers whereas in pneumonitis 9 (25%) were never, 24 (66.7%) former and 3 (8.3%) current smokers.

Univariate Analysis
-------------------

### Alpha-2-Macroglobulin

A significant correlation between baseline A2M values and esophagitis was found (Rs = −0.18/*p* = 0.003). Using a Wilcoxon rank-sum test, we found that patients with grade \<2 had significantly higher baseline serum A2M levels than patients with grade ≥2 esophagitis (*p* = 0.015) as shown in [Table 2](#T2){ref-type="table"}. No statistically significant difference was found between baseline A2M levels and grade ≥2 pneumonitis (*p* = 0.84).

###### 

Comparison of mean A2M serum levels \[mg/dL\] between grade \<2 and ≥2 esophagitis and pneumonitis.

  **Toxicity**              **Grade 0 or 1**   **Grade 2+**   ***p*-value**
  -------------- ---------- ------------------ -------------- ---------------
  Esophagitis    *N*        197                61             0.015
                 Mean A2M   208.9              190.4          
  Pneumonitis    *N*        222                36             0.837
                 Mean A2M   204.1              207.0          

*P-value was calculated using Wilcoxon rank-sum test*.

A trend between smoking status and A2M levels was observed. Current smokers had higher levels (217.3 mg/dl) compared to former (207.3 mg/dl) and never smokers (185.4 mg/dl), and former smokers had higher levels compared to never smokers. The A2M level had a significant correlation with a status of former/current smoker when compared to never smokers (Rs = 0.13/*p* = 0.04).

### Clinical Factors

Among standard clinical variables, the following variables showed significant correlations with grade ≥2 esophagitis: age (Rs = −0.32/*p* \< 0.0001), fraction number (Rs = 0.64/*p* \< 0.0001), treatment days (Rs = 0.60/*p* \< 0.0001), chemotherapy use (Rs = 0.56/*p* \< 0.0001), dose per fraction (Rs = −0.57/*p* \< 0.0001), and total dose (Rs = 0.35/*p* \< 0.0001), whereas for grade ≥2 pneumonitis, the only significant clinical variable was sex (Rs = −0.32/*p* = 0.037) with a higher risk for women.

### Dosimetric Factors

Spearman\'s correlation test between dosimetric variables in esophagus and esophagitis showed that all variables had Rs \> 0.60 (*p* \< 0.0001) as shown in [Figure 1A](#F1){ref-type="fig"}. For the fractional dose, fD40 was the highest correlated variable (Rs = 0.58/*p* \< 0.0001) as shown in [Figure 1B](#F1){ref-type="fig"}.

![Spearman\'s correlation coefficients. Spearman\'s correlation coefficients between radiation-induced injuries (≥ grade 2) and Dx in esophagus for **(A)** esophagitis, fDx in esophagus for **(B)** esophagitis, and Dx in lung and heart for **(C)** pneumonitis.](fonc-10-01395-g0001){#F1}

D15 (Rs = 0.19/*p* = 0.006) in lung and D45 (Rs = 0.16/*p* = 0.016) in heart were assessed as the highest correlated variables with pneumonitis for each organ ([Figure 1C](#F1){ref-type="fig"}). Maximum dose in heart was also significantly correlated with Rs = 0.14 (*p* = 0.043).

Multivariate Analysis and Validation Testing
--------------------------------------------

Hierarchical clustering coupled with Pearson\'s correlation test using training data was performed on dosimetric variables of each organ to measure variable similarity. Many dosimetric variables were highly correlated ([Supplementary Material 2](#SM2){ref-type="supplementary-material"}). Using a threshold of 0.75 in Pearson\'s correlation the variable with the highest Rs value for the endpoint among the variables in each cluster was selected. Clinical variables with *p* \< 0.1 in the univariate analysis and dosimetric variables left after the clustering test were used in the LASSO logistic regression: D25, D40, D50, D65, D85, fD10, fD25, fD35 in esophagus, age, total dose, and A2M for esophagitis; D10, D15, D65, D95 in lung, D20, D45, max dose in heart and sex for pneumonitis. For both endpoints, treatment days, SBRT (yes/no) and chemotherapy (yes/no) were used. Two variables including dose per fraction and number of fractions were excluded due to their high correlation with the number of treatment days.

LASSO logistic regression models were trained using bootstrapped datasets generated from training data and were tested on the validation data, resulting in an average AUC of 0.84 (standard deviation \[SD\] = 0.03) and 0.78 (SD = 0.06) for esophagitis and pneumonitis, respectively. Additional modeling was performed for esophagitis without A2M resulting in the same average AUC (0.84). This appears to be due to more significant dosimetric and clinical variables used in the modeling. To assess the importance of features, the frequency of occurrence of each feature during the model building process was counted ([Figure 2](#F2){ref-type="fig"}). For the esophagitis model, chemotherapy and treatment days were most frequently selected with 770 and 758 times from 1,000 different models, respectively. It is worth noting that A2M was selected 610 times, implying its likely association with esophagitis. For the pneumonitis model, D65 in lung and max dose in heart were most frequently selected with 865 and 798 times, respectively. Patients were sorted based on predicted outcomes on the validation data and grouped into six equal bins with one being the lowest risk group and six being the highest risk group. When comparing observed and predicted incidence, we found a high conformity of both endpoints, meaning that the predictive models are highly robust ([Figure 3](#F3){ref-type="fig"}). Final predictive models built using all training data are shown in [Table 3](#T3){ref-type="table"}. Interestingly, a variable of treatment days (between the start of RT and the end of RT including weekends) was selected in both models.

![Features in predictive models. Frequency of occurrence of each feature used in 1,000 predictive models for **(A)** esophagitis and **(B)** pneumonitis.](fonc-10-01395-g0002){#F2}

![Observed and predicted incidence. Comparison of observed and predicted incidence on validation data (1/3 of samples) for **(A)** esophagitis and **(B)** pneumonitis. Numerator, number of events in each bin; Denominator, number of samples in each bin.](fonc-10-01395-g0003){#F3}

###### 

Final predictive models for esophagitis and pneumonitis.

  **Variable**            **Coefficient**   **STD**   **Odds ratio**   **95% CI**   
  ----------------------- ----------------- --------- ---------------- ------------ -------
  **Esophagitis model**                                                             
  D25                     0.012             0.026     1.012            0.962        1.064
  D40                     0.036             0.022     1.037            0.993        1.083
  Treatment days          0.048             0.026     1.049            0.997        1.105
  Constant                −3.880            0.725     0.021            0.005        0.086
  **Pneumonitis model**                                                             
  D65 in lung             0.252             0.146     1.286            0.967        1.711
  Max dose in heart       0.015             0.008     1.015            0.999        1.032
  Treatment days          0.024             0.020     1.024            0.986        1.064
  Constant                −3.824            0.793     0.022            0.005        0.103

*CI, confidence interval; STD, standard deviation*.

In addition, the frequency of occurrence of each pair of features used in the LASSO logistic regression model was investigated ([Figure 4](#F4){ref-type="fig"}), which provides the information of interaction effects of features in the predictive model.

![Pairs of features in predictive models. Frequency of occurrence of a pair of features (divided by 1,000) used in 1,000 predictive models for **(A)** esophagitis and **(B)** pneumonitis.](fonc-10-01395-g0004){#F4}

Discussion {#s4}
==========

Taking into account the multifactorial etiology of radiation toxicity ([@B30]), it is essential to look at different predictive factors in the development of lung and esophageal injury after RT. Dosimetric parameters are most commonly included in predictive models but biological and genetic determinants are also under investigation ([@B9], [@B11], [@B30]--[@B37]). In our analysis, we focused on dose-volume metrics, age, chemotherapy, and other clinical variables in addition to the intrinsic radioprotectant A2M.

As we identified in our correlative analysis, baseline serum A2M levels appear to be influenced by patients\' smoking status. Former and current smokers displayed higher A2M values than patients that had never smoked. Active and former smoking has been associated with lower rates of grade ≥3 radiation pneumonitis compared to never smokers in patients with NSCLC after 3DCRT or IMRT ([@B38]). The effect of smoking on the immune system has been studied extensively. Paradoxically, smoking results in immunosuppression as well as aggravated autoimmunity. Altered levels of inflammatory cytokines like TNF-α, IFN-γ, IL-1β, IL-6, IL-8, IL-10, and others have been reported in healthy smokers ([@B39]--[@B42]). A possible explanation for the connection between active smoking and a lower risk for esophagitis or pneumonitis is that long-term cigarette smoking leads to an increased immune response in the lung and surrounding tissues due to the damage it inflicts on the lung parenchyma. Although the mechanisms resulting in normal tissue injury after RT are still under investigation, the release of reactive oxygen species (ROS) as well as proinflammatory and profibrotic cytokines is thought to have a central role in the process ([@B30]). Higher baseline levels of acute-phase proteins like A2M may have a protective effect on the irradiated tissue by binding proinflammatory and profibrotic cytokines, thus reducing the acute cytokine toxicity, and inducing an upregulation of antioxidant enzymes like manganese superoxide dismutase (MnSOD) ([@B23], [@B30]).

Our study suggests that there may be an association between natural pre-treatment baseline levels of the intrinsic radioprotectant serum A2M in patients with thoracic malignancies and an increased risk of developing radiation esophagitis. This association reached univariate statistical significance for esophagitis, but not for the pneumonitis endpoint. This finding indicates that higher levels of A2M may have a protective effect in patients undergoing thoracic RT. The high selection frequency of A2M in the model building process confirms our primary univariate analyses implying a likely correlation of A2M levels with esophagitis rates. Factors that have repeatedly shown significant correlation with esophagitis include V40--V60 ([@B6], [@B43]--[@B46]) (Vx: percentage volume receiving at least x Gy), mean esophageal dose ([@B47]--[@B49]), as well as sequential and especially concurrent chemoradiation in comparison to RT alone ([@B5], [@B6], [@B50]--[@B53]).

For pneumonitis, we validated the correlation with radiation dose received by the heart. Different lung dose volumes (V5--V40 and mean dose in lung) have been found to predict the development of pneumonitis ([@B7], [@B10], [@B54]). In addition, the dose received by the heart during thoracic radiation seems to be an accurate predictor ([@B55], [@B56]). The best fitting predictive model reported by Huang et al. included D10 (heart), D35 (lung) and max dose (lung), and had an AUC of 0.72 ([@B55]). Although the ideal dosimetric variable(s) for predicting pneumonitis across all patient subgroups may not yet be known, it is evident that heart doses are an essential part of any model built for this cause. Though we could not confirm the impact of A2M on pneumonitis with our data, a correlation between them has been previously described ([@B9], [@B56]). We may have been limited by the lower incidence of grade ≥2 pneumonitis (14.0%) and the low rate of current smokers in our patient cohort. In the previously published study on A2M and pneumonitis, pneumonitis rates were between 19 and 35%. The variable of sex was found to be correlated with pneumonitis in univariate analysis and had the third-highest frequency in 1,000 model runs ([Figure 2B](#F2){ref-type="fig"}), consistent with another study ([@B57]). However, its role as a risk factor for pneumonitis is controversial ([@B58]).

While all patients had A2M collected within 30 days prior to the start of RT and toxicity data were systematically prospectively graded per our clinical standard, caution is warranted regarding the interpretation of these results. In particular, including a factor like chemotherapy in predictive models should be considered carefully as different regimens, doses and timings, depending on the patient population, make it a very heterogeneous variable. Similarly, the patient cohort we studied was diverse regarding diagnosis and treatment. Although requirements for eligibility included no prior RT, patients underwent different modes of RT (3DCRT/SBRT/IMRT) which may have an impact on the toxicity profile. Furthermore, smoking status as a variable was not evenly distributed. Given its proposed link to serum A2M levels, this could be a cause for certain discrepancies in our results. A2M levels in humans reported in previous studies range on average between 100 and 450 mg/dL with a mean of around 215 mg/dL. Age and gender are known to influence this value with females generally showing around 20% higher levels than same-aged males ([@B59], [@B60]). Given the lack of data thus far concerning other factors that may influence intrinsic A2M levels, further analyses with serum levels recorded immediately prior to and while receiving RT are necessary.

In summary, the analysis of our institutional dataset has produced predictive models for both esophagitis and pneumonitis. Although the addition of A2M did not increase the predictive power of multivariate predictive models, this is the first report on the possible association of higher levels of A2M with a lower risk of radiation esophagitis and with smoking, warranting further investigation and independent validation.
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